Bextra

On May 9, 2005, Poyner Baxter filed a class action lawsuit against Pfizer Canada Inc. and Pfizer Inc. Pfizer researched, developed, manufactured, sold, distributed and/or marketed a drug called Bextra in Canada.

Bextra is a nonsteroidal, anti-inflammatory drug prescribed to relieve pain and swelling. It is typically used to treat arthritis, acute pain, acute migraine headaches, and menstrual pain and discomfort.

The lawsuit alleges that Bextra has been associated with an increased risk of serious adverse cardiovascular complications, as well as serious skin reactions, and that Pfizer knew or ought to have known at least as early as 2000 that there was a significant risk of these complications from ingesting Bextra.

In April of 2005, Health Canada asked the Defendant, Pfizer Canada Inc., to suspend sales of Bextra.  Pfizer Canada Inc. has agreed to discontinue sales of Bextra in Canada. On December 16, 2005, following a review of safety information, Health Canada issued a statement informing the public that it will not approve the return of Bextra to the marketplace.

To view the complete Statement of Claim, click here.

If you wish to be entered into our database of Bextra users please click here.

This Web site is offered for information only and is not legal advice. Use of the site and sending or receiving information through it does not establish an attorney-client relationship. No one should act, or refrain from acting, based solely upon this information without seeking appropriate legal or other professional advice. In particular, you should obtain advice about limitation periods as it may affect your right to bring a legal action on your own behalf. Links to and from from this Web site do not state or imply a relationship between Poyner Baxter LLP and the linked entity.

Back